Copeptin as a promising biomarker of cerebrovascular events: A minireview

Cerebrovascular events remain a major health issue, and despite significant improvements in diagnosis and treatment in recent years, their high morbidity and mortality mean that increasing attention is now being given to prevention and early prediction. One option for achieving this is to examine various biomarkers. This mini review covers copeptin, a 39-amino-acid glycopeptide, derived from the precursor protein pre-provasopressin. Copeptin shows great potential in the diagnosis and prognosis of diverse diseases, including cerebrovascular events. Compared to arginine vasopressin or cortisol alone, it shows better potential for use in emergency care due to its rapid determination. Understanding the role of copeptin and its clinical applications is essential for advancing patient care and treatment strategies. This mini review presents selected studies on the use of copeptin as a potential biomarker for cerebrovascular events. Its level correlates with the severity of both clinical and radiological impairment after a stroke. A correlation has been demonstrated between copeptin levels and the ability to predict a cerebrovascular event recurrence within 90 days after a transient ischemic attack. This mini review also includes the limits to copeptin, which are influenced by selected vascular risk factors for cerebrovascular events.